Equity Profile

FOLD

Amicus Therapeutics, Inc.

Health CareBiotechnology$4.5B

May4Mon

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EDT

Company Snapshot

Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will be watching closely to see if Amicus can maintain or improve its earnings.

$-0.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products. This quarter's revenue expectations will help gauge growth potential.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic diseases. With a market cap of $5 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

In the last quarter (Q4-2025), Amicus reported an EPS of $0.10, exceeding estimates by 49.25%. However, the stock saw a slight decline the following day, indicating mixed investor sentiment despite the earnings beat.

Management Promises & Guidance

Continued focus on advancing pipeline therapies.
Commitment to maintaining operational efficiency.
Plans to enhance market presence in rare disease treatments.

Expectations

Wall Street Expectations

Analysts expect Amicus to report a loss this quarter, with a consensus EPS of $-0.08 and revenue of $160 million. The market is cautiously optimistic given the company's recent performance.

Bull Case

If Amicus beats EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its growth trajectory and lead to a significant stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

$-0.08

EPS is a key indicator of the company's profitability and financial health. Investors will be watching closely to see if Amicus can maintain or improve its earnings.

Revenue

$160M

Revenue figures provide insight into the company's sales performance and market demand for its products. This quarter's revenue expectations will help gauge growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amicus achieve an EPS of $-0.08 or better this quarter?

A better-than-expected EPS could boost investor confidence and validate the company's growth strategy.

How does the revenue of $160 million compare to previous quarters?

Revenue growth is crucial for assessing the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to recent advancements in Amicus's pipeline, which could lead to stronger-than-expected sales.

Supporting Evidence

Recent earnings surprises indicate a trend of exceeding expectations.

The company's focus on rare diseases may position it favorably in a niche market.

Options pricing suggests lower volatility than historical averages, indicating a potential mispricing of risk.

Key Risk

If revenue exceeds $160 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the backdrop of recent earnings surprises.

Bull Confirmed If

Achieving an EPS of $-0.08 or better, alongside revenue exceeding $160 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than $-0.08 and revenue below $149 million would indicate significant challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that investors are uncertain about the outcome.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average one-day move of +1.13%, confirming a positive sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with history suggesting an average one-day drop of -6.51%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of pipeline therapies and their expected launch timelines.
2Any commentary on market demand for existing products.
3Insights into operational efficiencies and cost management strategies.
4Future guidance on revenue expectations for the upcoming quarters.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Amicus Therapeutics, Inc. (FOLD) is a biotechnology company focused on developing therapies for rare genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will be watching closely to see if Amicus can maintain or improve its earnings.

$-0.08

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products. This quarter's revenue expectations will help gauge growth potential.

$160M

Wall Street expectations, options signals, track record, and call prep available with Pro.

FOLD Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+157.80%

Avg Stock Reaction

-1.80%

Last Quarter Recap

Management Promises & Guidance

Continued focus on advancing pipeline therapies.
Commitment to maintaining operational efficiency.
Plans to enhance market presence in rare disease treatments.

Expectations

Wall Street Expectations

Analysts expect Amicus to report a loss this quarter, with a consensus EPS of $-0.08 and revenue of $160 million. The market is cautiously optimistic given the company's recent performance.

Bull Case

If Amicus beats EPS expectations and shows strong revenue growth, it could signal robust demand for its therapies and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its growth trajectory and lead to a significant stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

$-0.08

EPS is a key indicator of the company's profitability and financial health. Investors will be watching closely to see if Amicus can maintain or improve its earnings.

Revenue

$160M

Revenue figures provide insight into the company's sales performance and market demand for its products. This quarter's revenue expectations will help gauge growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amicus achieve an EPS of $-0.08 or better this quarter?

A better-than-expected EPS could boost investor confidence and validate the company's growth strategy.

How does the revenue of $160 million compare to previous quarters?

Revenue growth is crucial for assessing the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth due to recent advancements in Amicus's pipeline, which could lead to stronger-than-expected sales.

Supporting Evidence

Recent earnings surprises indicate a trend of exceeding expectations.

The company's focus on rare diseases may position it favorably in a niche market.

Options pricing suggests lower volatility than historical averages, indicating a potential mispricing of risk.

Key Risk

If revenue exceeds $160 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the backdrop of recent earnings surprises.

Bull Confirmed If

Achieving an EPS of $-0.08 or better, alongside revenue exceeding $160 million, would confirm a positive outlook.

Bear Confirmed If

An EPS worse than $-0.08 and revenue below $149 million would indicate significant challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±3.8%

Historical Avg

±5.5%

Pricing cheap

The options market is pricing in a modest move around the earnings report, suggesting that investors are uncertain about the outcome.

Options are pricing ±3.8% while FOLD has averaged ±5.5% over the last 8 prints — setup is pricing cheap.

Detail

30d HV

1.7%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amicus beats expectations, history suggests a potential average one-day move of +1.13%, confirming a positive sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss could lead to a decline in stock price, with history suggesting an average one-day drop of -6.51%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of pipeline therapies and their expected launch timelines.
2Any commentary on market demand for existing products.
3Insights into operational efficiencies and cost management strategies.
4Future guidance on revenue expectations for the upcoming quarters.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.